AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9817404 — intervention group
Group type: EXPERIMENTAL
Intervention: 48-hour tirilazad mesylate (48TM)
Number of subjects: 0
Study 9817404 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 8929934 — intervention group
Group type: EXPERIMENTAL
Intervention: High attendance or Enhanced Care group (average of 4.1 treatment days per week)
Number of subjects: 0
Study 8929934 — intervention group
Group type: COMPARATOR
Intervention: Low attendance or Usual Care and Medium attendance groups (less than one treatment day per week)
Number of subjects: 0
Study 2781424 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone 4 mg
Number of subjects: 11
Study 2781424 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 30575978 — intervention group
Group type: EXPERIMENTAL
Intervention: E6011 (0.0006-10 mg/kg)
Number of subjects: 64
Study 30575978 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 29247083 — intervention group
Group type: EXPERIMENTAL
Intervention: Allen Carr's Easyway programme
Number of subjects: 0
Study 29247083 — intervention group
Group type: COMPARATOR
Intervention: 1-1 counselling service via the National Health Service
Number of subjects: 0
Study 26425688 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant 5-fluorouracil (5FU)
Number of subjects: 572
Study 23478870 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral group intervention for children (child-only intervention)
Number of subjects: 194
Study 23478870 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral group intervention for children (parent-child intervention)
Number of subjects: 194
Study 23478870 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 194
Study 21440702 — intervention group
Group type: EXPERIMENTAL
Intervention: Constraint‐Induced Movement Therapy (CIMT)
Number of subjects: 64
Study 21440702 — intervention group
Group type: COMPARATOR
Intervention: Bimanual training
Number of subjects: 64
Study 21440702 — intervention group
Group type: EXPERIMENTAL
Intervention: CIMT
Number of subjects: 64
Study 19567922 — intervention group
Group type: EXPERIMENTAL
Intervention: CHO supplemented
Number of subjects: 7
Study 19567922 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 16941239 — intervention group
Group type: EXPERIMENTAL
Intervention: PRT with the recommended therapist voice (RV)
Number of subjects: 48
Study 16941239 — intervention group
Group type: EXPERIMENTAL
Intervention: PRT with conversational therapist voice (CV)
Number of subjects: 48
Study 16941239 — intervention group
Group type: COMPARATOR
Intervention: Systematic self-relaxation (SR)
Number of subjects: 48
Study 16941239 — intervention group
Group type: COMPARATOR
Intervention: No treatment control (NT)
Number of subjects: 48
Study 16281522 — intervention group
Group type: EXPERIMENTAL
Intervention: Methanthelinium bromide 50 mg orally twice daily for 4 weeks
Number of subjects: 41
Study 16281522 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 16281522 — intervention group
Group type: EXPERIMENTAL
Intervention: Methanthelinium bromide
Number of subjects: 41
Study 11136321 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk adenomas
Number of subjects: 442
Study 9289631 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% sucralfate suspension
Number of subjects: 28
Study 9289631 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 gram sucralfate chewable tablets
Number of subjects: 28
Study 8214949 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen (prostaglandin synthetase inhibitor)
Number of subjects: 14
Study 8214949 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 3612641 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivitamin/multimineral with 65 mg of iron
Number of subjects: 42
Study 3612641 — intervention group
Group type: COMPARATOR
Intervention: Multivitamin without iron
Number of subjects: 42
Study 29792908 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg caffeine
Number of subjects: 40
Study 29792908 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 27856807 — intervention group
Group type: EXPERIMENTAL
Intervention: High-resistance-moderate-endurance (Re)
Number of subjects: 80
Study 27856807 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-endurance-moderate-resistance (re)
Number of subjects: 80
Study 27856807 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-resistance-high-endurance (rE)
Number of subjects: 80
Study 27856807 — intervention group
Group type: EXPERIMENTAL
Intervention: All training modalities (combined)
Number of subjects: 80
Study 26263033 — intervention group
Group type: EXPERIMENTAL
Intervention: NPPV (inspiratory/expiratory positive airway pressure of 28.2 ± 2.8 / 5.5 ± 1.5 mbar)
Number of subjects: 15
Study 26263033 — intervention group
Group type: COMPARATOR
Intervention: Supplemental oxygen (2.4 ± 0.7 L/min)
Number of subjects: 15
Study 23857313 — intervention group
Group type: EXPERIMENTAL
Intervention: Dichoptic treatment combined with visual cortex direct current stimulation
Number of subjects: 16
Study 23857313 — intervention group
Group type: COMPARATOR
Intervention: Dichoptic treatment alone
Number of subjects: 16
Study 21149659 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel plus trastuzumab
Number of subjects: 284
Study 21149659 — intervention group
Group type: COMPARATOR
Intervention: Vinorelbine plus trastuzumab
Number of subjects: 284
Study 19213337 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese recipe for RSRCC
Number of subjects: 64
Study 19213337 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 64
Study 16339469 — intervention group
Group type: EXPERIMENTAL
Intervention: Task-specific training with trunk restraint (TR)
Number of subjects: 30
Study 16339469 — intervention group
Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 30
Study 14564317 — intervention group
Group type: EXPERIMENTAL
Intervention: Q-wave MI
Number of subjects: 13100
Study 14564317 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-Q-wave MI
Number of subjects: 13100
Study 14564317 — intervention group
Group type: EXPERIMENTAL
Intervention: Q-wave MI with complete ST-segment resolution
Number of subjects: 13100
Study 14564317 — intervention group
Group type: EXPERIMENTAL
Intervention: Q-wave MI with partial ST-segment resolution
Number of subjects: 13100
Study 14564317 — intervention group
Group type: EXPERIMENTAL
Intervention: Q-wave MI with no ST-segment resolution
Number of subjects: 13100
Study 14564317 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-Q-wave MI with complete ST-segment resolution
Number of subjects: 13100
Study 14564317 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-Q-wave MI with partial ST-segment resolution
Number of subjects: 13100
Study 14564317 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-Q-wave MI with no ST-segment resolution
Number of subjects: 13100
Study 11113042 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary stenting
Number of subjects: 620
Study 11113042 — intervention group
Group type: COMPARATOR
Intervention: Balloon angioplasty
Number of subjects: 620
Study 11113042 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon angioplasty followed by stenting (after optimization)
Number of subjects: 620
Study 11113042 — intervention group
Group type: COMPARATOR
Intervention: Balloon angioplasty without stenting (after optimization)
Number of subjects: 620
Study 11113042 — intervention group
Group type: COMPARATOR
Intervention: Provisional angioplasty
Number of subjects: 620
Study 8853223 — intervention group
Group type: EXPERIMENTAL
Intervention: ondansetron 0.25 mg bd
Number of subjects: 111
Study 8853223 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 111
Study 1740401 — intervention group
Group type: EXPERIMENTAL
Intervention: Instantaneous rise time at 60 dB
Number of subjects: 120
Study 1740401 — intervention group
Group type: EXPERIMENTAL
Intervention: Instantaneous rise time at 95 dB
Number of subjects: 120
Study 1740401 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 ms rise time at 60 dB
Number of subjects: 120
Study 1740401 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 ms rise time at 95 dB
Number of subjects: 120
Study 1740401 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (combined analysis)
Number of subjects: 120
Study 6096517 — intervention group
Group type: EXPERIMENTAL
Intervention: VP-16-213
Number of subjects: 165
Study 29544506 — intervention group
Group type: EXPERIMENTAL
Intervention: Responsive Parenting (RP) intervention
Number of subjects: 279
Study 27094920 — intervention group
Group type: EXPERIMENTAL
Intervention: High social status position (HIGH)
Number of subjects: 9
Study 27094920 — intervention group
Group type: COMPARATOR
Intervention: Low social status position (LOW)
Number of subjects: 9
Study 25342704 — intervention group
Group type: EXPERIMENTAL
Intervention: High protein (HP) beverage (1.5 g/100 ml)
Number of subjects: 13
Study 25342704 — intervention group
Group type: EXPERIMENTAL
Intervention: Low protein (LP) beverage (0.75 g/100 ml)
Number of subjects: 13
Study 25342704 — intervention group
Group type: COMPARATOR
Intervention: Control (CON) beverage (0 g/100 ml)
Number of subjects: 13
Study 23576048 — intervention group
Group type: EXPERIMENTAL
Intervention: Casein (30 g, 15N-labeled)
Number of subjects: 13
Study 23576048 — intervention group
Group type: COMPARATOR
Intervention: Whey proteins (30 g)
Number of subjects: 13
Study 19924001 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stent (Xience V)
Number of subjects: 213
Study 19924001 — intervention group
Group type: COMPARATOR
Intervention: Bare metal stent (Multilink Vision)
Number of subjects: 213
Study 19035944 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine use of episiotomy
Number of subjects: 200
Study 19035944 — intervention group
Group type: COMPARATOR
Intervention: Restrictive use of episiotomy
Number of subjects: 200
Study 16810594 — intervention group
Group type: EXPERIMENTAL
Intervention: V-system
Number of subjects: 50
Study 16810594 — intervention group
Group type: COMPARATOR
Intervention: Conventional duodenoscope
Number of subjects: 50
Study 12642251 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone sodium phosphate (40 mA-minutes)
Number of subjects: 199
Study 12642251 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 199
Study 11118468 — intervention group
Group type: EXPERIMENTAL
Intervention: myeloablative chemoradiotherapy with autologous purged bone marrow rescue
Number of subjects: 466
Study 11118468 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive blood immunocytology at diagnosis
Number of subjects: 466
Study 9188997 — intervention group
Group type: COMPARATOR
Intervention: 0.2 mg/kg midazolam
Number of subjects: 17
Study 9188997 — intervention group
Group type: COMPARATOR
Intervention: 0.3 mg/kg midazolam
Number of subjects: 17
Study 1540363 — intervention group
Group type: EXPERIMENTAL
Intervention: Heated Humidifier (HH)
Number of subjects: 51
Study 1540363 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat and Moisture Exchanger (HME)
Number of subjects: 51
Study 1540363 — intervention group
Group type: COMPARATOR
Intervention: No warming device (Control)
Number of subjects: 51
Study 3698751 — intervention group
Group type: EXPERIMENTAL
Intervention: Long intestinal (Cantor) tube preoperatively
Number of subjects: 138
Study 3698751 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasogastric tube placed intraoperatively
Number of subjects: 138
Study 3698751 — intervention group
Group type: COMPARATOR
Intervention: No gastrointestinal tube at all
Number of subjects: 138
Study 31669738 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced recovery after surgery
Number of subjects: 118
Study 31669738 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 118
Study 29331328 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Flow Nasal Cannula (HFNC) oxygen therapy
Number of subjects: 62
Study 29331328 — intervention group
Group type: COMPARATOR
Intervention: Conventional oxygen therapy (control)
Number of subjects: 62
Study 28440216 — intervention group
Group type: EXPERIMENTAL
Intervention: Transseptal suturing
Number of subjects: 62
Study 28440216 — intervention group
Group type: COMPARATOR
Intervention: Nasal packing
Number of subjects: 62
Study 24608960 — intervention group
Group type: EXPERIMENTAL
Intervention: Efavirenz 600 mg daily
Number of subjects: 540
Study 23022104 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 M, pH 1.0 HCl
Number of subjects: 90
Study 23022104 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 N, pH 13.0 NaOCl
Number of subjects: 90
Study 23022104 — intervention group
Group type: COMPARATOR
Intervention: Deionized water (pH 6.9)
Number of subjects: 90
Study 21351264 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen treatment
Number of subjects: 328
Study 21351264 — intervention group
Group type: COMPARATOR
Intervention: No adjuvant treatment
Number of subjects: 328
Study 18051216 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT) with a high-dose, standardized, 3-grass pollen extract
Number of subjects: 127
Study 18051216 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 127
Study 16087920 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodopa (single oral dose)
Number of subjects: 0
Study 16087920 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10930797 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Number of subjects: 187
Study 10930797 — intervention group
Group type: COMPARATOR
Intervention: Doxorubicin
Number of subjects: 187
Study 9305335 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin 600 mg/d
Number of subjects: 275
Study 9305335 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin 1200 mg/d
Number of subjects: 275
Study 9305335 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin 2400 mg/d
Number of subjects: 275
Study 9305335 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin (all dosages combined)
Number of subjects: 275
Study 8339575 — intervention group
Group type: EXPERIMENTAL
Intervention: Vancomycin
Number of subjects: 58
Study 8339575 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 58
Study 30509271 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin (25 mg daily)
Number of subjects: 40
Study 30509271 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (2000 mg daily)
Number of subjects: 40
Study 30509271 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin/Metformin (25 mg and 2000 mg daily, respectively)
Number of subjects: 40
Study 30509271 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 26751068 — intervention group
Group type: EXPERIMENTAL
Intervention: H2025A (infant formula fortified with DHA and ARA, DHA/ARA ratio of 2:1)
Number of subjects: 35
Study 26751068 — intervention group
Group type: COMPARATOR
Intervention: Control formula (infant formula fortified only with DHA)
Number of subjects: 35
Study 26751068 — intervention group
Group type: EXPERIMENTAL
Intervention: H2025A
Number of subjects: 35
Study 26751068 — intervention group
Group type: COMPARATOR
Intervention: Control formula
Number of subjects: 35
Study 23086332 — intervention group
Group type: EXPERIMENTAL
Intervention: Vertise Flow (VF, Kerr)
Number of subjects: 32
Study 23086332 — intervention group
Group type: COMPARATOR
Intervention: G-Bond (GB, GC)
Number of subjects: 32
Study 23086332 — intervention group
Group type: COMPARATOR
Intervention: AdheSE One (AO, Ivoclar Vivadent)
Number of subjects: 32
Study 23086332 — intervention group
Group type: COMPARATOR
Intervention: Adper Easy Bond (EB, 3M ESPE)
Number of subjects: 32
Study 23086332 — intervention group
Group type: COMPARATOR
Intervention: Xeno V (XV, Dentsply)
Number of subjects: 32
Study 23086332 — intervention group
Group type: COMPARATOR
Intervention: iBOND (iB, Heraeus Kulzer)
Number of subjects: 32
Study 21946199 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional therapy + anti-Helicobacter pylori therapy
Number of subjects: 0
Study 21946199 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 0
Study 18455083 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride
Number of subjects: 0
Study 18455083 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 16269526 — intervention group
Group type: EXPERIMENTAL
Intervention: Jump training (10 maximum vertical jumps/day, 3 times/week for 6 months)
Number of subjects: 36
Study 16269526 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 36
Study 12673718 — intervention group
Group type: EXPERIMENTAL
Intervention: CD38 high expression (> or = 20%)
Number of subjects: 120
Study 12673718 — intervention group
Group type: EXPERIMENTAL
Intervention: CD38 low expression (< 20%) with low CD31 expression (< 76%)
Number of subjects: 120
Study 12673718 — intervention group
Group type: EXPERIMENTAL
Intervention: CD38 low expression (< 20%) with high CD31 expression
Number of subjects: 120
Study 12673718 — intervention group
Group type: EXPERIMENTAL
Intervention: CD31 expression
Number of subjects: 120
Study 10868867 — intervention group
Group type: EXPERIMENTAL
Intervention: Active PENS treatment
Number of subjects: 50
Study 10868867 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 50
Study 9568325 — intervention group
Group type: EXPERIMENTAL
Intervention: Active phase hypertrophic scars
Number of subjects: 0
Study 9568325 — intervention group
Group type: COMPARATOR
Intervention: Remission phase hypertrophic scars
Number of subjects: 0
Study 9568325 — intervention group
Group type: COMPARATOR
Intervention: Normotrophic scars
Number of subjects: 0
Study 8173690 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine-metoprolol combination tablet (extended-release), administered once daily, dosage individually titrated until blood pressure control achieved.
Number of subjects: 337
Study 8173690 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine-metoprolol combination tablet (extended-release) for 24 months (Swedish/UK study).
Number of subjects: 337
Study 8173690 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine-metoprolol combination tablet (extended-release) with hydrochlorothiazide added if necessary (12.5 or 25 mg daily).
Number of subjects: 337
Study 8173690 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine-metoprolol combination tablet (extended-release).
Number of subjects: 337
Study 3325175 — intervention group
Group type: EXPERIMENTAL
Intervention: amikacin + ceftazidime
Number of subjects: 60
Study 3325175 — intervention group
Group type: EXPERIMENTAL
Intervention: amikacin + aztreonam
Number of subjects: 60
Study 3325175 — intervention group
Group type: EXPERIMENTAL
Intervention: amikacin + piperacillin
Number of subjects: 60
Study 30122799 — intervention group
Group type: EXPERIMENTAL
Intervention: Bridges (1:1 savings match)
Number of subjects: 1383
Study 30122799 — intervention group
Group type: EXPERIMENTAL
Intervention: Bridges PLUS (1:2 savings match)
Number of subjects: 1383
Study 30122799 — intervention group
Group type: EXPERIMENTAL
Intervention: Bridges and Bridges PLUS
Number of subjects: 1383
Study 30122799 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 1383
Study 26908839 — intervention group
Group type: EXPERIMENTAL
Intervention: Gonadotropin suppression (testosterone enanthate + GnRH antagonist acyline)
Number of subjects: 22
Study 26908839 — intervention group
Group type: EXPERIMENTAL
Intervention: Gonadotropin suppression (testosterone enanthate + progestin levonorgestrel)
Number of subjects: 22
Study 26908839 — intervention group
Group type: EXPERIMENTAL
Intervention: Gonadotropin suppression (testosterone enanthate + levonorgestrel + GnRH antagonist acyline)
Number of subjects: 22
Study 26908839 — intervention group
Group type: EXPERIMENTAL
Intervention: Gonadotropin suppression (testosterone enanthate + levonorgestrel + 5α‐reductase inhibitor dutasteride)
Number of subjects: 22
Study 26908839 — intervention group
Group type: COMPARATOR
Intervention: Control group (7 men)
Number of subjects: 22
Study 24509717 — intervention group
Group type: EXPERIMENTAL
Intervention: Accurate instructions
Number of subjects: 0
Study 24509717 — intervention group
Group type: EXPERIMENTAL
Intervention: Inaccurate instructions
Number of subjects: 0
Study 24509717 — intervention group
Group type: EXPERIMENTAL
Intervention: Pliance instructions
Number of subjects: 0
Study 24509717 — intervention group
Group type: COMPARATOR
Intervention: Tracking instructions
Number of subjects: 0
Study 23358784 — intervention group
Group type: EXPERIMENTAL
Intervention: Managed Problem Solving (MAPS)
Number of subjects: 180
Study 23358784 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 180
Study 20586934 — intervention group
Group type: EXPERIMENTAL
Intervention: Entecavir 0.5 mg/day
Number of subjects: 519
Study 20586934 — intervention group
Group type: COMPARATOR
Intervention: Lamivudine 100 mg/day
Number of subjects: 519
Study 18380628 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Number of subjects: 0
Study 18380628 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin
Number of subjects: 0
Study 18380628 — intervention group
Group type: COMPARATOR
Intervention: Pravastatin
Number of subjects: 0
Study 18380628 — intervention group
Group type: COMPARATOR
Intervention: Simvastatin
Number of subjects: 0
Study 20688040 — intervention group
Group type: EXPERIMENTAL
Intervention: LEISH-F1+MPL-SE vaccine (5, 10, or 20 μg recombinant Leishmania polyprotein LEISH-F1 antigen + 25 μg MPL-SE adjuvant)
Number of subjects: 44
Study 20688040 — intervention group
Group type: EXPERIMENTAL
Intervention: LEISH-F1+MPL-SE vaccine
Number of subjects: 44
Study 20688040 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant alone
Number of subjects: 44
Study 20688040 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 44
Study 16118921 — intervention group
Group type: EXPERIMENTAL
Intervention: Phacotrabeculectomy from single incision
Number of subjects: 41
Study 16118921 — intervention group
Group type: COMPARATOR
Intervention: Phacotrabeculectomy and phacoemulsification from two separate incisions
Number of subjects: 41
Study 12127611 — intervention group
Group type: EXPERIMENTAL
Intervention: Ir-192
Number of subjects: 252
Study 12127611 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 252
Study 12127611 — intervention group
Group type: EXPERIMENTAL
Intervention: Ir-192 (Diabetic patients)
Number of subjects: 252
Study 12127611 — intervention group
Group type: EXPERIMENTAL
Intervention: Ir-192 (Nondiabetic patients)
Number of subjects: 252